90 related articles for article (PubMed ID: 11697650)
41. 19-Nor-1,25(OH)2D2 (a novel, noncalcemic vitamin D analogue), combined with arsenic trioxide, has potent antitumor activity against myeloid leukemia.
Kumagai T; Shih LY; Hughes SV; Desmond JC; O'Kelly J; Hewison M; Koeffler HP
Cancer Res; 2005 Mar; 65(6):2488-97. PubMed ID: 15781666
[TBL] [Abstract][Full Text] [Related]
42. Mechanism of adenosine triphosphate catabolism induced by deoxyadenosine and by nucleoside analogues in adenosine deaminase-inhibited human erythrocytes.
Bontemps F; Van den Berghe G
Cancer Res; 1989 Sep; 49(18):4983-9. PubMed ID: 2788493
[TBL] [Abstract][Full Text] [Related]
43. Influence of treatment with 3'-deoxyadenosine associated deoxycoformycin on hematological parameters and activity of adenosine deaminase in infected mice with Trypanosoma evansi.
Dalla Rosa L; Da Silva AS; Ruchel JB; Gressler LT; Oliveira CB; França RT; Lopes ST; Leal DB; Monteiro SG
Exp Parasitol; 2013 Oct; 135(2):357-62. PubMed ID: 23933282
[TBL] [Abstract][Full Text] [Related]
44. Enhancement of manumycin A-induced apoptosis by methoxyamine in myeloid leukemia cells.
She M; Pan I; Sun L; Yeung SC
Leukemia; 2005 Apr; 19(4):595-602. PubMed ID: 15744347
[TBL] [Abstract][Full Text] [Related]
45. Combination of 22-oxa-1,25-dihydroxyvitamin D(3), a vitamin D(3) derivative, with vitamin K(2) (VK2) synergistically enhances cell differentiation but suppresses VK2-inducing apoptosis in HL-60 cells.
Funato K; Miyazawa K; Yaguchi M; Gotoh A; Ohyashiki K
Leukemia; 2002 Aug; 16(8):1519-27. PubMed ID: 12145693
[TBL] [Abstract][Full Text] [Related]
46. Activation of deoxycytidine kinase by deoxyadenosine: implications in deoxyadenosine-mediated cytotoxicity.
Keszler G; Virga S; Spasokoukotskaja T; Bauer PI; Sasvari-Szekely M; Staub M
Arch Biochem Biophys; 2005 Apr; 436(1):69-77. PubMed ID: 15752710
[TBL] [Abstract][Full Text] [Related]
47. S-adenosylhomocysteine catabolism and basis for acquired resistance during treatment of T-cell acute lymphoblastic leukemia with 2'-deoxycoformycin alone and in combination with 9-beta-D-arabinofuranosyladenine.
Hershfield MS; Kredich NM; Koller CA; Mitchell BS; Kurtzberg J; Kinney TR; Falletta JM
Cancer Res; 1983 Jul; 43(7):3451-8. PubMed ID: 6601986
[TBL] [Abstract][Full Text] [Related]
48. Protection by various deoxynucleosides against deoxyadenosine-induced DNA damage in adenosine deaminase-inactivated lymphocytes.
Shimoyama RK; Seto S; Mori C
Mol Genet Metab; 1999 Dec; 68(4):455-60. PubMed ID: 10607474
[TBL] [Abstract][Full Text] [Related]
49. Carbonyl reductase 1 offers a novel therapeutic target to enhance leukemia treatment by arsenic trioxide.
Jang M; Kim Y; Won H; Lim S; K R J; Dashdorj A; Min YH; Kim SY; Shokat KM; Ha J; Kim SS
Cancer Res; 2012 Aug; 72(16):4214-24. PubMed ID: 22719067
[TBL] [Abstract][Full Text] [Related]
50. Enhancement of the biological activity of adenosine analogs by the adenosine deaminase inhibitor 2'-deoxycoformycin.
Adamson RH; Zaharevitz DW; Johns DG
Pharmacology; 1977; 15(1):84-9. PubMed ID: 840892
[TBL] [Abstract][Full Text] [Related]
51. A novel ring-substituted diindolylmethane,1,1-bis[3'-(5-methoxyindolyl)]-1-(p-t-butylphenyl) methane, inhibits extracellular signal-regulated kinase activation and induces apoptosis in acute myelogenous leukemia.
Contractor R; Samudio IJ; Estrov Z; Harris D; McCubrey JA; Safe SH; Andreeff M; Konopleva M
Cancer Res; 2005 Apr; 65(7):2890-8. PubMed ID: 15805291
[TBL] [Abstract][Full Text] [Related]
52. 2-Chloro-2'-deoxyadenosine (2CdA) biochemical aspects of antileukemic efficacy.
Fabianowska-Majewska K; Wyczechowska D
Acta Pol Pharm; 1996; 53(4):231-9. PubMed ID: 9415193
[TBL] [Abstract][Full Text] [Related]
53. Requirement for caspase activation in monocytic differentiation of myeloid leukemia cells.
Pandey P; Nakazawa A; Ito Y; Datta R; Kharbanda S; Kufe D
Oncogene; 2000 Aug; 19(34):3941-7. PubMed ID: 10951587
[TBL] [Abstract][Full Text] [Related]
54. B cells as well as T cells form deoxynucleotides from either deoxyadenosine or deoxyguanosine.
Goday A; Simmonds HA; Morris GS; Fairbanks LD
Clin Exp Immunol; 1984 Apr; 56(1):39-48. PubMed ID: 6424986
[TBL] [Abstract][Full Text] [Related]
55. Ajoene, a garlic-derived natural compound, enhances chemotherapy-induced apoptosis in human myeloid leukaemia CD34-positive resistant cells.
Ahmed N; Laverick L; Sammons J; Zhang H; Maslin DJ; Hassan HT
Anticancer Res; 2001; 21(5):3519-23. PubMed ID: 11848518
[TBL] [Abstract][Full Text] [Related]
56. Importance of MEK-1/-2 signaling in monocytic and granulocytic differentiation of myeloid cell lines.
Miranda MB; McGuire TF; Johnson DE
Leukemia; 2002 Apr; 16(4):683-92. PubMed ID: 11960350
[TBL] [Abstract][Full Text] [Related]
57. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib.
Zhang GS; Liu DS; Dai CW; Li RJ
Am J Hematol; 2006 Apr; 81(4):242-55. PubMed ID: 16550520
[TBL] [Abstract][Full Text] [Related]
58. WP-1034, a novel JAK-STAT inhibitor, with proapoptotic and antileukemic activity in acute myeloid leukemia (AML).
Faderl S; Ferrajoli A; Harris D; Van Q; Priebe W; Estrov Z
Anticancer Res; 2005; 25(3B):1841-50. PubMed ID: 16158916
[TBL] [Abstract][Full Text] [Related]
59. Induction of apoptosis by cordycepin in ADA-inhibited TdT-positive leukemia cells.
Koç Y; Urbano AG; Sweeney EB; McCaffrey R
Leukemia; 1996 Jun; 10(6):1019-24. PubMed ID: 8667637
[TBL] [Abstract][Full Text] [Related]
60. A small-molecule c-Myc inhibitor, 10058-F4, induces cell-cycle arrest, apoptosis, and myeloid differentiation of human acute myeloid leukemia.
Huang MJ; Cheng YC; Liu CR; Lin S; Liu HE
Exp Hematol; 2006 Nov; 34(11):1480-9. PubMed ID: 17046567
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
